Suggested remit: To appraise the clinical and cost effectiveness of nivolumab in combination with ipilimumab within its marketing authorisation for untreated advanced unresectable recurrent or metastatic oesophageal cancer.
As you will be aware The Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab with platinum-based chemotherapy for advanced unresectable, recurrent or metastatic previously untreated oesophageal cancer [ID2712] and Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]. Please note that following on from information received from the company, these appraisals have been combined and will be appraised as one Single Technology Appraisal [ID2712]. The timelines have been revised and the appraisal is now anticipated to begin in mid- January 2022 when we will write to stakeholders about how they can get involved.
 
Status Suspended
Process STA 2018
ID number 1629

Project Team

Project lead Michelle Adhemar

Timeline

Key events during the development of the guidance:

Date Update
05 October 2021 Suspended. As you will be aware The Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab with platinum-based chemotherapy for advanced unresectable, recurrent or metastatic previously untreated oesophageal cancer [ID2712] and Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]. Please note that following on from information received from the company, these appraisals have been combined and will be appraised as one Single Technology Appraisal [ID2712]. The timelines have been revised and the appraisal is now anticipated to begin in mid- January 2022 when we will write to stakeholders about how they can get involved.
16 April 2021 - 17 May 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
14 July 2020 Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.
24 January 2020 In progress. Topic is in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance